ArticleJACC. Case reports2026
Transcatheter Tricuspid Valve Replacement in Rheumatic Tricuspid Valve Regurgitation.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The "Cairo Accord"- towards the eradication of RHD: revisited (2026).Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatic heart disease (RHD) is a leading cause of valvular heart disease worldwide, particularly in developing countries. The mitral and aortic valves are most often affected; however, tricuspid valve involvement has been observed in advanced cases. CASE SUMMARY: We present a case of a patient with RHD with tricuspid valve involvement who successfully underwent transcatheter tricuspid valve replacement (TTVR). DISCUSSION: TTVR is a promising, less-invasive alternative treatment for patients with severe symptomatic tricuspid regurgitation deemed unsuitable for surgery. Despite the increasing adoption of TTVR, patients with RHD are frequently excluded from major clinical trials, leading to limited evidence supporting the use of this intervention in this population. TAKE-HOME MESSAGES: As TTVR technology advances, its application in RHD warrants further exploration. The routine exclusion of RHD patients or pathology from TTVR clinical trials should also be reconsidered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.